Skip to main content
. Author manuscript; available in PMC: 2021 Oct 3.
Published in final edited form as: Breast Cancer Res Treat. 2021 May 10;188(3):615–630. doi: 10.1007/s10549-021-06239-y

Table 2.

Spearman’s rho correlation coefficient and P value between Miller-Payne grade and tumor Nottingham grade, tumor subtypes (HER2, ER, TNBC), pre-treatment HbT, oxyHb, deoxyHb, %HbT measured at end of cycles (EOCs) 1–3 and post-treatment HbT and %HbT. Pre-treatment US, %US measured at the end of cycle 1–3, and post-treatment US and %US

Predictors
Biomarkers US predictors Hemoglobin predictors
Nottingham grade
rho = 0.260 (P = 0.115)
HER2
rho = 0.336 (P = 0.039)
ER
rho = 0.341 (P = 0.036)
TNBC
rho = 0.245 (P = 0.138)		 Pre-treatment US
rho = − 0.408 (P = 0.011)
%US_EOC1
rho = − 0.461 (P = 0.005)
%US_EOC2
rho = − 0.346 (P = 0.045)
%US_EOC3
rho = − 0.420 (P = 0.013)
Post-treatment US
rho = − 0.416 (P = 0.012)
Post-treatment %US
rho = − 0.270 (P = 0.111)		 Pre-treatment HbT
rho = 0.358 (P = 0.028)
Pre-treatment oxyHb
rho = 0.278 (P = 0.091)
Pre-treatment deoxyHb
rho = 0.249 (P = 0.132)
%HbT_EOC1
rho = − 0.513 (P = 0.001)
%HbT_EOC2
rho = − 0.587 (P < 0.001)
%HbT_EOC3
rho = − 0.731 (P < 0.001)
Post-treatment HbT
rho = − 0.094 (P = 0.592)
Post-treatment %HbT
rho = − 0.445 (P = 0.007)

Data were from this study of total 38 patients